UNLIMITED TURBO LONG - UCB Stock

P5LIB

NLBNPNL20I29

Real-time Euronext Paris 03:38:15 2024-05-08 EDT
11.88 ^EUR	+0.76%

Current month	-7.49%
1 month	+11.49%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	01:04am	PU
UCB - Acquisition of own shares	05-06	AQ
UCB : Acquisition of own shares	04-26	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	04-26	PU

More news

Quotes 5-day view

Date	Price	Change	Volume
24-05-08	11.88	+0.76%	13
24-05-07	11.79	+0.94%	91
24-05-06	11.68	-2.26%	85
24-05-03	11.95	-2.13%	95
24-05-02	12.21	-4.20%	105

Real-time Euronext Paris

Last update May 08, 2024 at 03:38 am

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	P5LIB
ISIN	NLBNPNL20I29
Date issued	2022-08-19
Strike	62.24 €
Maturity	Unlimited
Parity	5 : 1
Emission price	3.08 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	12.82 €
Lowest since issue	1.04 €
Spread	0.02 €
Spread %	0.17%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

119.9 EUR

Average target price

125.5 EUR

Spread / Average Target

+4.67%

Consensus